Novelion Therapeutics (NVLN) Getting Somewhat Positive Press Coverage, Accern Reports
Media headlines about Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novelion Therapeutics earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.9697376190768 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of research firms have recently issued reports on NVLN. ValuEngine cut shares of Novelion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 12th. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $9.00 price target on shares of Novelion Therapeutics in a research report on Tuesday, October 3rd. Finally, Zacks Investment Research cut shares of Novelion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th.
Shares of Novelion Therapeutics (NVLN) traded up $0.14 during midday trading on Friday, reaching $3.64. 128,171 shares of the company traded hands, compared to its average volume of 108,587. Novelion Therapeutics has a twelve month low of $3.25 and a twelve month high of $12.12. The company has a current ratio of 1.45, a quick ratio of 1.28 and a debt-to-equity ratio of 6.53.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.
Receive News & Ratings for Novelion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.